Apr 08
Health Canada has initiated a safety review on tofacitinib
Health Canada is informing Canadians and health care professionals that it is conducting a safety review of Xeljanz and Xeljanz XR (tofacitinib) after a clinical trial identified an increased risk of serious heart-related issues and cancer in trial participants.Xeljanz and Xeljanz XR (tofacitinib...
Health Canada